Table 3.
SBRT publications for treatment of prostate cancer with 5 year actuarial %FFBF.
| Study author | Patient population | Number of patients | Dose | Median follow-up (months) | 5-year %FFBF |
||
|---|---|---|---|---|---|---|---|
| Low | Intermediate | High | |||||
| Freeman and King (5) | Low risk only, 2 institutions | 41 | 35Gy/5, 36.25Gy/5 | 60 | 93 | – | – |
| Kang et al. (18) | 3 risk groups, single institution | 44 | 32Gy/4, 34 Gy/4, 36Gy/4 | 40 | 100 | 100 | 91 |
| King et al. (6) | 3 risk groups, 8 institutions | 1100 | 36.25Gy/4–5 | 36 | 95 | 84 | 81 |
| Katz et al. (19) | 3 risk groups, single institution | 304 | 35Gy/5, 36.25Gy/5 | 60 | 97 | 91 | 74 |
| Current study | 3 risk groups, single institution | 142 | 35Gy/5, 36.25Gy/5, 37.5Gy/5 | 38 | 94 | 94* | 84 |
*Seven patients with T2c only included in intermediate group as per new NCCN guidelines.